Page 12 - VISION Ausgabe 5

PUBLIKATIONEN

Publikationen 2019 - 2020

1 Jahr - 49 Publikationen - eine hervorragende Bilanz!

TPK Hegewisch-Becker S, Aldaoud A, Wolf T, et al 2019. G-CSF Day Egerer G, Uleer C, Klausmann M, et al, 2019.
Results from the Prospective German TPK Clinical Cohort Study: Treatment Algorithms and Prophylaxe von Chemotherapie-induzierter Neutropenie und febriler Neutropenie mit langwirk-
Survival of 1,174 Patients with Locally Advanced, Inoperable, or Metastatic Pancreatic Ductal samem G-CSF bei mit Chemotherapie behandelten Patienten in Deutschland: Ergebnisse der
Adenocarcinoma. International Journal of Cancer 144, Nr. 5 (2019): 981–90. epidemiologischen Querschnittsevaluation „G-CSF Day". Oncol Res Treat 2019;42(suppl 4):1-336
NADIR Wolff T, Schulz H, Losem C, et al, 2019. CARAT Goebell PJ, Müller L, Grüllich C, et al, 2019.
Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim Advanced renal cell carcinoma: first results from the prospective research platform CARAT for
in patients with non-Hodgkin lymphoma (NADIR study). Eur J Haematol 102(2), 174–181. patients with mRCC in Germany. Ann Oncol, Volume 30, v392
EVERPRO Goebell PJ, Hermann E, Kube U, et al, 2019. INGE-B Lüftner D, Welslau M, Liersch R, et al, 2019.
Final Results of a Non-Interventional Study Evaluating the Quality of Life in Second-line Treat- Palbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced,
ment of Metastatic Renal Cell Carcinoma With Everolimus: The EVERPRO Study. inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B
Oncol Res Treat 42(1–2). phase 2 study. Ann Oncol, Volume 30, v135
TKK Marschner N, Frank M, Vach W, et al, 2019. CRISP Griesinger F, Eberhardt WEE, Nusch A, et al, 2019.
A novel prognostic score for patients with metastatic colorectal cancer. Patients with metastatic non-small cell lung cancer and targetable molecular alterations in Ger-
Colorectal Dis. 2019 Jul; 21(7): 816–826. many. Treatment and first outcome data from the prospective German Registry Platform CRISP
(AIO-TRK-0315). Ann Oncol. 2019;30 (suppl. 5)(1552P (ID: 3764)):mdz260.074
LICC Schimanski CC, Kasper S, Hegewisch-Becker S, et al, 2019.
A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant im- CRISP Sebastian M, Eberhardt WEE, Losem C, et al, 2019.
munotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy Patients with metastatic non-small cell lung cancer and PD-L1 expression in Germany. Treatment
(LICC): Final results. J Clin Oncol 37 (4_suppl)(480). and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315).
Ann Oncol. 2019;30 (suppl. 5)(1519P (ID: 3970)):mdz260.041.
TLK Steffens C-C, Elender C, Hutzschenreuter U, et al, 2019.
Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, CRISP Griesinger F, Eberhardt WEE, Bruch HR, et al, 2019.
second and third line - Results from the prospective German TLK cohort study. Patients with metastatic non-small cell lung cancer without molecular alterations or PD-L1
Lung Cancer 130 (2019) 216-225. expression in Germany. Treatment and first outcome from the prospective German Registry
Platform CRISP (AIO-TRK-0315). Ann Oncol. 2019;30 (suppl. 5)(1500P (ID: 3775)):mdz260.022
LICC Moehler M, Folprecht M, Heinemann V, et al, 2019.
Survival after secondary liver resection in metastatic colorectal cancer. A comparative analysis TKK Borchert K, Jacob C, Wetzel N, et al, 2019.
of the LICC trial with historical controls (CELIM, FIRE-3). J Clin Oncol 37 (4_suppl)(571). Application study of the EQ-5D-5L in Oncology: Linking self-reported quality of life of patients
with advanced or metastatic colorectal cancer to clinical data from a german tumor registry:
TMK Marschner N, Trarbach T, Rauh J, et al, 2019. Results from a TOBIT regression. Value in Health, Volume 20, Issue 9, A456.
Quality of life in pre- and postmenopausal patients with early breast cancer: a comprehensive
analysis from the prospective MaLife project. Breast Cancer Res Treat. 2019; 175(3): 701–712. TLN Knauf W, Abenhardt W, Mohm J, et al, 2019.
Similar effectiveness of R-CHOP-14 and -21 in diffuse large B-cell lymphoma—data from the
VICTORIA Decker T, Marschner N, Muendlein A, et al, 2019. prospective German Tumour Registry Lymphatic Neoplasms. Eur J Haematol 00, 1–12.
VicTORia: A Randomised Phase II Study to Compare Vinorelbine in Combination with the MTOR
Inhibitor Everolimus versus Vinorelbine Monotherapy for Second-Line Chemotherapy in Advan- TNK Staehler M, Goebell PJ, Müller L, et al, 2019.
ced HER2-Negative Breast Cancer. Breast Cancer Res Treat, 176(3):637-64 2019. Rare patients in routine care - Treatment and outcome in advanced papillary renal cell carcino-
ma in the prospective German clinical RCC-Registry. Int J Cancer 146, Issue 5, 1307-1315.
IDELA Hoechstetter M, Knauf W, Eissmann P, et al, 2019.
Patient-based prospective real-world data analysis shows that the duration of treatment TMK Marschner N, Zacharias S, Welt A, et al, 2019.
interruptions with subsequent resumption of idelalisib therapy can vary from days to months. Negative impact of disease progression on quality of life of patients with advanced breast
HemaSphere 3 (PS1163), 528–529. cancer - Data from the TMK/MaLife project. The Breast 48 (suppl2), 71.
INGE-B Welt A, Welslau M K, Lüftner D, et al, 2019. OPAL Stickeler E, Harbeck N, Thill M, et al, 2019.
Palbociclib plus fulvestrant as first-line therapy for patients with locally advanced, inoperable Therapy of advanced breast cancer for patients with hormone receptor-positive / HER2-negative
or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study. and HER2-positive tumors is changing real life. First results from the prospective, national
Ann Oncol Volume 30, Issue Supplement_3, May 2019 research platform OPAL for patients with advanced breast cancer in Germany.
Cancer Res (80) (4 Supplement) P2-17-01
PAZOREAL Boegemann M, Bedke J, Schostak M, et al, 2019.
Sequential treatment with pazopanib (PAZO) followed by nivolumab (NIVO) in patients with INGE-B Welslau M, Marschner N, Söling U, et al, 2019.
advanced or metastatic renal cell carcinoma (mRCC): Third interim results of the non-interventi- Palbociclib in combination with anastrozole or exemestane for patients with locally advanced,
onal study PAZOREAL. J Clin Oncol 2019 37:15_suppl, 4574-4574 inoperable or metastatic HR+/HER2- breast cancer in Germany. Interim results of the INGE-B
phase 2 trial. Cancer Res 2020 (80) (4 Supplement) P5-11-14
TMK Overkamp F, Frühauf S, Fietz T, et al, 2019.
Pertuzumab beim HER2-positiven metastasierten Mammakarzinom in der Routinebehandlung – INGE-B Welt A, Welslau M, Lüftner D, et al, 2020.
Daten aus dem Tumorregister Mammakarzinom. Senologie 2019; 16(02): 31 - 31 Palbociclib plus fulvestrant as first-line therapy for patients with locally advanced, inoperable
or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study.
FIRST-NIS Nückel H, Hurtz H-J, Schulz H, et al, 2019. Oncol Res Treat 43 (suppl 1)(270), 13–14.
Lenalidomide in combination with dexamethasone as first-line therapy in transplant-ineli-
gible patients with Multiple Myeloma: Interim Results of the observational study FIRST-NIS. INGE-B Lüftner D, Welslau M, Liersch R, et al, 2020.
HemaSphere. 3():263–264, Palbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced,
inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B
CARO Knauf W, Ammon A, Uhlig J, et al; 2019. phase 2 study. Oncol Res Treat 43 (suppl 1)(272), 14.
Twice weekly carfilzomib is an accepted treatment by patients with Multiple Myeloma who have
received at least one prior therapy: Interim results of the CARO study. STEFANO Zaiss M, Uhlig J, Zahn M-O, et al, 2020.
HemaSphere. 3():646–647 Reduction of severity of chemotherapy-induced peripheral neuropathy by OnLife®14.02.2020
Final results of the breast cancer cohort of the STEFANO trial.
LICC Schimanski CC, Kasper S, Hegewisch-Becker S, et al, 2019. Oncol Res Treat 43 (suppl 1)(405), 185.
A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant im- OPAL
munotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy Decker T, Harbeck, N, Thill, et al, 2020.
(LICC): Final results. Journal of Clinical Oncology 37, no. 15_suppl (May 20 2019) 3537-3537. Routine care of advanced breast cancer: the prospective, national research platform OPAL for
patients with advanced breast cancer in Germany. Oncol Res Treat 43(suppl 1)(254), 12.
TKK Dörfel S, Fruehauf S, Sauer A, et al, 2019.
Behandlungsrealität und Überleben von Drittlinienpatienten mit metastasiertem kolorektalem CRISP Sebastian M, Eberhardt WEE, Losem C, et al, 2020.
Karzinom - Daten aus dem klinischen Tumorregister Kolorektales Karzinom (TKK) Patients with metastatic non-small cell lung cancer and PD-L1 expression in Germany. Treatment
Oncol Res Treat 42 (suppl.4) and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315)
Oncol Res Treat. 2020 Feb;43 (suppl. 1)(P394):114.
CRISP Griesinger F, Eberhardt WEE, Nusch A, et al, 2019.
Patients with metastatic non-small cell lung cancer and targetable oncogenic molecular altera- CRISP Griesinger F, Eberhardt WEE, Nusch A, et al, 2020.
tions in Germany. Treatment and first outcome data from the prospective German Registry CRISP Patients with metastatic non-small cell lung cancer and targetable molecular alterations in
(AIO-TRK-0315). Oncol Res Treat. 2019;42 (suppl. 4)(P399):107 Germany. Treatment and first outcome data from the prospective German Registry Platform
CRISP (AIO-TRK-0315) Oncol Res Treat. 2020 Feb;43 (suppl. 1)(P393):114.
CRISP Sebastian M, Eberhardt WEE, Losem C, et al, 2019.
Patients with metastatic non-small cell lung cancer and targetable oncogenic molecular altera- CRISP Griesinger F, Eberhardt WEE, Bruch HR, et al, 2020.
tions in Germany. Treatment and first outcome data from the prospective German Registry CRISP Patients with metastatic non-small cell lung cancer without molecular alterations or PD-L1
(AIO-TRK-0315). Oncol Res Treat. 2019;42 (suppl. 4)(P413):113 expression in Germany. Treatment and first outcome from the prospective German Registry
Platform CRISP (AIO-TRK-0315) Oncol Res Treat. 2020 Feb;43 (suppl. 1)(P395):115
CRISP Griesinger F, Eberhardt WEE, Bruch HR, et al, 2019.
Patients with metastatic non-small cell lung cancer without molecular alterations or PD-L1 MYRIAM Knauf W, Engelhardt M, Losem C, et al, 2020.
expression in Germany. Treatment and first outcome from the prospective German Registry The Prospective Intersectoral National Cohort Study MYRIAM To Study Characteristics, Treat-
Platform CRISP (AIO-TRK-0315). Oncol Res Treat. 2019;42 (suppl. 4)(P405):109 ment And Outcome Of Patients With Multiple Myeloma In Germany.
Oncol Res Treat 43 (suppl 1)(392), 130.
MYRIAM Engelhardt M, Knauf W, Lipke J, et al, 2019.
MyLife: Longitudinal assessment of health-related quality of life in patients with multiple TKK Zahn M-O, Dörfel S, Schulz H, et al, 2020.
myeloma in Germany – First patient-reported outcomes data from MYRIAM, the prospective, Real-world testing patterns for BRAF-mutations and treatment of patients with BRAF-mutated
national, intersectoral cohort study for treatment and outcome of myeloma patients. Oncol Res metastatic colorectal cancer: Results from the German Tumor Registry Colorectal Cancer (TKK
Treat 42 (suppl 4)(P713), 193. Registry). Oncol Res Treat 43(suppl 1)(426), 52.
TLN Knauf W, Abenhardt W, Koenigsmann M, et al, 2019. NEPTUN Dechow T, Riera-Knorrenschild J, Hackanson B, et al, 2020.
Patients with Marginal Zone Lymphoma: Characteristics, treatment reality and outcome data Nab-paclitaxel plus carboplatin as first-line therapy for patients with advanced NSCLC in the
from the German prospective TLN Registry. Oncol Res Treat 42 (suppl 4)(P695), 185 real-world setting: Safety results of the non-interventional NEPTUN study.
Oncol Res Treat 43 (suppl 1)(276), 112.
TPK Jänicke M, Zacharias S, Hamm D, Marschner N, 2019.
Scheinbar stabile Lebensqualität durch Datenverzerrung bei Patienten mit fortgeschrittenem CONVENIENCE Metz M, Semsek D, Hutzschenreuter U, et al, 2020.
Pankreaskarzinom - Daten aus dem klinischen Tumorregister Pankreaskarzinom (TPK). Administration of pegfilgrastim prophylaxis via pre-filled syringe (Neulasta®) or On-body injec-
Oncol Res Treat 42 (suppl.4) tor (OBI): Interim results on patient preference and health economics from the CONVENIENCE
study. Oncol Res Treat 43 (suppl 1)(458), 185.
CONVENIENCE Metz M, Semsek D, Hutzschenreuter U, et al, 2019.
Applikation der Pegfilgrastim Prophylaxe mittels Spritze (Neulasta®) oder On-Body-Injektor CARAT Goebell PJ, Grüllich C, Reichert D, et al, 2020.
(OBI): Interimsergebnisse zu Patientenpräferenz und Gesundheitsökonomie der CONVENIENCE Advanced renal cell carcinoma: first results from the prospective research platform CARAT for
Studie. Oncol Res Treat 2019;42(suppl 4):1-336 patients with mRCC in Germany. Oncol Res Treat 43 (suppl 1)(391), 76.
Register- Marschner N, Zacharias S, Lordick F, et al, 2020.
übergreifend Association of Disease Progression With Health-Related Quality of Life Among Adults With
Breast, Lung, Pancreatic, and Colorectal Cancer. JAMA Network Open 3, Nr. 3: e200643–
e200643.
12